POLLUX/CASTOR: Daratumumab Improved Myeloma Outcomes Regardless of Risk Group

Video
Conference|ASCO Annual Meeting: Hematology

This video presents updated results of two phase III trials in relapsed or refractory multiple myeloma, showing the impact of daratumumab combinations across cytogenetic risk groups.

In this video, Katja Weisel, MD, of the University of Tübingen in Germany, reviews updated results of two phase III trials in relapsed or refractory multiple myeloma that revealed the impact of daratumumab combinations across cytogenetic risk groups.

POLLUX tested daratumumab in combination with lenalidomide plus dexamethasone (DRd) vs lenalidomide plus dexamethasone (Rd). Patients on this trial had a median of 1 prior treatment.

CASTOR tested daratumumab in combination with bortezomib plus dexamethasone (DVd) vs bortezomib plus dexamethasone (Vd). Patients on this trial had a median of 2 prior treatments and 42% of patients had already been treated with lenalidomide.

Weisel presented results of the study (abstract 8006) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Recent Videos
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Related Content
Outcomes of haploidentical vs. mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis

Outcomes of haploidentical vs. mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis

American Society for Transplantation and Cellular Therapy
October 31st 2025
Article

Researchers have determined that donor age has a stronger, nonlinear impact on OS vs donor type in allogeneic HCT using posttransplant cyclophosphamide for GVHD prophylaxis, with donor type becoming increasingly relevant in older donors.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

Outlining Considerations for the Rare Lymphoma Treatment Paradigm

Roman Fabbricatore
October 17th 2025
Article

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Site Logo

Prognosis Strategy Exhibits Similar Transplant Outcomes in Select Patients

Roman Fabbricatore
October 5th 2025
Article

A study by the Blood and Marrow Transplant Clinical Trials Network found that a donor search prognosis strategy may move those with cancer to HCT faster.

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

FDA Receives BLA for Pivekimab Sunirine in Rare Hematologic Malignancy

Russ Conroy
October 1st 2025
Article

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.